AFYA Afya Ltd

Swedbank AB recently initiated a new stake in Afya Limited (NASDAQ:AFYA), purchasing 70,000 shares valued at approximately $1.09 million during the third quarter, representing a 0.07% ownership. This move highlights significant institutional interest in Afya, with 88.02% institutional ownership and other funds like Goldman Sachs and Carrera Capital also increasing their positions. Analysts currently rate Afya as a "Moderate Buy" with a consensus price target of $18.75.

Afya Limited (NASDAQ:AFYA) has received an average "Moderate Buy" rating from six research firms, with an average 12-month price target of $18.75. JPMorgan upgraded Afya to Overweight with a $24.50 target, while UBS moved it to Buy, setting a target of $19.00. The stock has a market cap of $1.38 billion, a P/E ratio of 10.58, and approximately 88% of its shares are held by institutions and hedge funds.

Perpetual Ltd significantly reduced its stake in Afya Limited by selling 84,892 shares in Q3, now holding 66,288 shares valued at approximately $1.03 million. Despite this, Afya maintains a "Moderate Buy" consensus rating from analysts with an average price target of $18.75. The company's stock trades within a 52-week range of $13.47–$19.90, has a market cap of $1.36 billion, and institutional investors hold 88.02% of the stock.

Wall Street Zen has downgraded Afya (NASDAQ:AFYA) from a "strong-buy" to a "buy" rating. Despite this, the stock holds a "Moderate Buy" consensus rating from analysts with a target price of $18.75, trading near $14.56 with high institutional ownership. Afya is a leading provider of medical education in Brazil, and its stock is down about 0.5%.

Afya Ltd. (AFYA) announced strong Q3 2025 results, with EPS of $2.08 significantly exceeding the forecast of $1.76, and revenue reaching $928.51 million against an anticipated $924.61 million. Following this positive performance, Afya's stock rose by 1.52% in after-hours trading. The company highlighted strong growth in both revenue and net income, alongside continued expansion in medical education and digital solutions, and discussed future plans including tuition increases and potential M&A activities.

Afya Ltd. reported strong Q3 2025 results, exceeding analyst expectations with double-digit growth in revenue and adjusted EBITDA, along with margin expansion. The company's financial strategy includes a significant debt restructuring, and it is navigating regulatory challenges related to Brazil's OECD Pillar Two Rules while pursuing future growth through tuition increases and potential M&A. Afya, a leading medical education company in Brazil, continues to strengthen its market position with a comprehensive ecosystem.